Despite market uncertainty, healthcare CEOs of all stripes remain upbeat about 2019
The market gyrations, the shutdown, the trade war, the Texas judge - nothing can get these four healthcare CEOs down as they look at 2019.
For CAR-Ts to be successful, figuring out manufacturing is key
Efficacy, safety and reimbursement are all important things for CAR-T makers to figure out, but manufacturing is no less important.
Improving the Healthcare Financial Experience to Help Care Flow
Zelis CEO Amanda Eisel shares her perspective on how the company is solving the problems of a fragmented health financial system to benefit all.
Cell, gene therapies demand creative payment models, but implementing them is a challenge, CEOs say
Performance- and time-based payment models - like the one bluebird bio has proposed for LentiGlobin - are especially harder to put into practice in the US than in Europe, some executives said at this week's JPM conference.
What does the $74B BMS-Celgene deal mean for 2019? Investors at JPM weigh in
After a bruising second half of the year, more biotech companies could be targeted for buys, along with the possibility of additional large deals.
Can direct-to-consumer models work in digital health?
A panel of investors at the Digital Health Showcase in San Francisco weighed in where a direct-to-consumer model remains viable in digital health.
Precision medicine is “not at loggerheads” with population health
The founding dean of the nation's first college of population health explains that precision medicine and population health are in reality synergistic concepts.
presented by
What Keeps Healthcare CIOs Up at Night: Balancing Technology Investments with Consumer Expectations
When it comes to managing inbound phone calls, underperformance has devastating cost implications.
Here’s Otsuka’s digital health strategy around mental health
Otsuka's top U.S.-based leaders spoke about the company's partnerships in mental health and how it is driving innovation in big pharma.
Where tech-enabled Medicaid innovation is sorely needed
The Future of Medicaid Innovation Forum was held in San Francisco during the J.P. Morgan Healthcare Conference to convene Medicaid innovators and highlight the areas of highest need.
Biopharma, healthcare CEOs tout value-based care at JPM
Fully incorporating value into pricing will require significant effort and investment, the Novartis CEO said. Meanwhile, CVS/Caremark's Larry Merlo said the company's acquisition of Aetna opened opportunities for innovative pricing models.
Lilly chief at JPM: conditions ‘ripe’ for M&A uptick in 2019
CEO David Ricks advocates careful approach focused on differentiation of assets in breakout session, while CFO says company has capacity for one transaction per quarter.
Using Data to Help Healthcare Practices Succeed
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
Dr. Toby Cosgrove: I really dislike the term disruptor
Dr. Toby Cosgrove and other healthcare experts muse on data analytics, tech entrants, healthcare incumbents and more on the digital health panel at the annual J.P. Morgan healthcare conference.
Foundation Medicine appoints new CEO; exec provides forecasts for precision medicine in 2019
With the approval of Loxo's Vitrakvi, pan-cancer drugs and an emphasis on real-world data are likely to become important trends trends this year.
In JPM interview, Gottlieb outlines FDA efforts to promote biopharma competition
The agency plans to release several guidances on complex generics and biosimilars, along with taking a deep dive into the Orange Book patent and exclusivity database.
Challenges and opportunities in FDA’s new digital health regulations
A range of companies at the Digital Health showcase in San Francisco discussed how they view the changing regulatory environment within the category of software as a medical device.
Artificial Intelligence and healthcare — impending revolution or hype machine?
During a drug’s journey from bench to bedside, there are multiple touchpoints where machine learning can provide value. It can be difficult to decipher which AI tools in development stand to offer real advances and where AI’s benefits have been exaggerated.